Vaccine advisers to the U.S. Centers for Disease Control and Prevention voted 15-0 Thursday to change recommendations for COVID-19 vaccines to make clear that shots made by Moderna and Pfizer/BioNTech are preferred over Johnson & Johnson's vaccine.The new recommendation: "mRNA vaccines are preferred over the Janssen COVID-19 vaccine for the prevention of Covid-19 for those 18 years of age and over."Related video above: Omicron spreads 70 times faster than delta in certain respiratory tissue, researchers sayThe CDC's Advisory Committee on Immunization Practices endorsed the updated recommendation after hearing new data indicating that a rare blood clotting syndrome is more common among people who recently got a J&J vaccine than previously believed. The CDC has logged 54 cases in the U.S. of thrombosis with thrombocytopenia syndrome or TTS in the U.S. since the vaccine became available. Nine people have died -- seven women and two men.ACIP members considered the new data and weighed it against numerous studies showing J&J's vaccine is less effective than the Moderna and Pfizer/BioNTech vaccines in preventing infection. They also discussed the risks of completely removing J&J's vaccine as an option, as well as the potential confusion and mistrust that might be caused by changing recommendations about the vaccine."We will absolutely emphasize how important education around the risk of these events is," the CDC's Dr. Sara Oliver told the meeting.Earlier this week, the U.S. Food and Drug Administration strengthened language in the fact sheet that goes along with the Janssen vaccine, saying it should not be given to anyone with a history of TTS.
Vaccine advisers to the U.S. Centers for Disease Control and Prevention voted 15-0 Thursday to change recommendations for COVID-19 vaccines to make clear that shots made by Moderna and Pfizer/BioNTech are preferred over Johnson & Johnson's vaccine.
The new recommendation: "mRNA vaccines are preferred over the Janssen COVID-19 vaccine for the prevention of Covid-19 for those 18 years of age and over."
Related video above: Omicron spreads 70 times faster than delta in certain respiratory tissue, researchers say
The CDC's Advisory Committee on Immunization Practices endorsed the updated recommendation after hearing new data indicating that a rare blood clotting syndrome is more common among people who recently got a J&J vaccine than previously believed. The CDC has logged 54 cases in the U.S. of thrombosis with thrombocytopenia syndrome or TTS in the U.S. since the vaccine became available. Nine people have died -- seven women and two men.
ACIP members considered the new data and weighed it against numerous studies showing J&J's vaccine is less effective than the Moderna and Pfizer/BioNTech vaccines in preventing infection. They also discussed the risks of completely removing J&J's vaccine as an option, as well as the potential confusion and mistrust that might be caused by changing recommendations about the vaccine.
"We will absolutely emphasize how important education around the risk of these events is," the CDC's Dr. Sara Oliver told the meeting.
Earlier this week, the U.S. Food and Drug Administration strengthened language in the fact sheet that goes along with the Janssen vaccine, saying it should not be given to anyone with a history of TTS.
Source link
